Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal.

Jesus Paez-Mayorga

Houston Methodist Research Institute

Jocelyn Campa-Carranza

Houston Methodist Research Institute

Simone Capuani

Houston Methodist Research Institute

Nathanael Hernandez

Houston Methodist Research Institute

Ying Chua

Fernanda Pons-Faudoa

Houston Methodist Research Institute <https://orcid.org/0000-0002-5135-9481>

Gulsah Malgir

Houston Methodist Research Institute

Bella Alvarez

Houston Methodist Research Institute

Jean Niles

Houston Methodist Research Institute

Kathryn Shelton

MD Anderson Cancer Center

Sarah Kezar

Michael E. Keeling Center for Comparative Medicine and Research, MD Anderson Cancer Center

Pramod Nehete

MD Anderson Cancer Center

Dora Berman-Weinberg

University of Miami

Xian Li

Houston Methodist Research Institute

Camillo Ricordi

University of Miami Miller School of Medicine

Joan Nichols

Houston Methodist Research Institute

Ahmed Gaber

Houston Methodist Research Institute

Norma Kenyon

University of Miami

Alessandro Grattoni (✉ agrattoni@houstonmethodist.org)

Houston Methodist Research Institute <https://orcid.org/0000-0001-7888-422X>

Article

Keywords: Cell encapsulation, beta cell, implantable device, vascularization, mesenchymal stem cells

Posted Date: February 2nd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1285406/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Communications on December 26th, 2022. See the published version at <https://doi.org/10.1038/s41467-022-35629-z>.

Abstract

Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need for systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, which integrates direct vascularization for facile mass transfer and localized immunosuppressant delivery for islet rejection prophylaxis. Here, we investigated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent rat model. We demonstrated that polyamide is superior to resin for NICHE subQ integration and vascularization. We demonstrated allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and reverted diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppression prevented islet rejection without inducing toxicity or systemic immunosuppression. Moreover, for translatability efforts, we showed NICHE biocompatibility and feasibility of deployment, as well as short-term allogeneic islet engraftment in an MHC-mismatched nonhuman primate model. In sum, the NICHE is a safe and effective platform for islet transplantation and long-term T1D management.

Introduction

Clinical pancreatic islet transplantation (CIT) holds promise to transform type 1 diabetes (T1D) management. In CIT, isolated islets are transplanted into the portal circulation and engraft passively in hepatic sinusoids. As pancreatic islets provide dynamic glucose control, CIT significantly improves glycemic profile, decreases hypoglycemic events, and reduces progression of diabetes-related comorbidities¹. However, hypoxia-related graft attrition and need for systemic immunosuppression limit its widespread clinical adoption. Specifically, systemic immunosuppression is toxic and leaves patients susceptible to life-threatening opportunistic infection and neoplasm development^{2,3}. In fact, immune suppression-related adverse effects are detrimental to the point CIT is often reserved for patients already receiving immunosuppression to sustain other transplanted organs.

Pancreatic islet encapsulation promises to overcome the need for toxic systemic immunosuppression regimens⁴. Most encapsulation strategies rely on physical immunoisolation; where islets are enveloped in semipermeable materials that permit oxygen, nutrient, and metabolite exchange, yet limit immune cell infiltration^{5,6}. However, impaired diffusion kinetics through the encapsulating material and within the implant compromise long-term cell viability. Moreover, foreign body reaction (FBR) to the encapsulating material engenders pericapsular fibrotic overgrowth, which further hinders mass transfer and exacerbates graft hypoxia⁷. As a result, conscientious efforts have been made to reduce graft site hypoxia through exogenous oxygen supplementation, in situ oxygen generation, mathematical modeling-based design optimization, and material modification to enhance peri-implant vascularization⁸⁻¹¹. Although these efforts are promising, the clinical success of physical immunoisolation has been limited.

Pancreatic islets are densely vascularized in their native state and secrete paracrine signals through intra-capillary networks¹². Thus, recent focus has shifted to strategies that permit blood vessel penetration

through the encapsulating material for direct islet revascularization^{13,14}. Apposition of islets to blood vessels grants them a virtually infinite supply of oxygen and nutrients to sustain metabolic capacity and anti-diabetogenic function. However, vascular integration inherently exposes the graft to the immune system, requiring systemic immunosuppression to prevent rejection.

Taken together, there is an unmet need for an encapsulation approach that integrates facile mass transfer to maintain graft function and effective immune evasion to prevent rejection. To meet this need, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device^{15–17}. The NICHE is a dual reservoir device integrating direct vascularization for oxygen and metabolite exchange and localized immunosuppressant delivery for islet rejection prophylaxis. Vascularization of the NICHE central cell reservoir is achieved by leveraging the pro-angiogenic properties of a mesenchymal stem cell (MSC) hydrogel, while integration of an interconnected outer drug reservoir permits direct and local immunosuppressant delivery into the cell reservoir through a nanoporous membrane (Fig. 1a).

Here, we demonstrated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent rat model. We investigated the use of two materials, acrylic resin and polyamide (PA) for NICHE manufacturing and demonstrated PA is superior for our approach. We also demonstrated allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and reverted diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppression prevented islet rejection without inducing systemic immunosuppression. For translatability efforts, we showed NICHE biocompatibility and feasibility of deployment, as well as short-term allogeneic islet engraftment in an MHC-mismatched nonhuman primate model.

Results

NICHE fabrication and characterization

To integrate direct vascularization and local immunosuppression, the NICHE was designed as a dual reservoir platform (Fig. 1a). An external *U*-shaped drug reservoir, where immunosuppressive drugs are loaded, surrounds a central cell reservoir, where islets are transplanted. The cell reservoir is enclosed by a two-layer mesh: an inner 300 μm x 300 μm mesh provides structural support, while an outer 100 μm x 100 μm mesh facilitates vascular tissue penetration and islet retention. The drug and cell reservoirs are interconnected by 1 x 1 mm openings along each longitudinal side of the drug reservoir, for a net exchange surface area of 8 mm². Moreover, each longitudinal side has nanoporous membranes affixed over the aforementioned openings to permit concentration-driven diffusion of immunosuppressants into the cell reservoir for localized immunosuppression. Finally, biocompatible, self-sealing silicone plugs in the drug and cell reservoirs permit minimally invasive, transcutaneous access for immunosuppressant replenishment and islet transplantation.

The NICHE was designed for subcutaneous (SubQ) deployment to minimize procedure invasiveness and was fabricated via additive manufacturing (otherwise known as 3D printing) to facilitate design

optimization and scalability. As such, we explored the use of two biocompatible, 3D printable materials previously employed by our group to fabricate implantable devices: a photopolymeric acrylic resin and PA 2200^{17,18}. Firstly, we assessed the tissue reactivity towards subQ implanted resin and PA devices in rats. For comparison, medical grade titanium (Ti) implants were used as controls. After 6 weeks of implantation, the fibrotic layers around resin and Ti devices were ~50 µm thick and mainly composed of dense collagen (Fig. 1b, d and Supplementary 1). In contrast, PA devices had ~2-fold thicker fibrotic layers (~114 µm) that were dense only at the tissue-material interphase (<5 cells in thickness), while lax and vascularized in the remaining portion (Fig. 1c, d). Implant reactivity scoring performed by a blinded, board-certified pathologist showed resin and PA devices had comparable tissue reactivity to Ti control (Fig. 1e). Moreover, both resin and PA had minimal immune cell infiltration and no adjacent tissue necrosis or inflammation (Supplementary 1), indicating that both materials were biocompatible and well tolerated.

Next, we explored the integration and vascularization of resin and PA NICHE into the subQ space. We previously demonstrated that device implantation with MSCs significantly enhances subQ integration and cell reservoir vascularity^{17,19}. As such, we implanted MSC-loaded resin and PA NICHE subQ in rats for 6 weeks. Gross examination of explanted NICHE revealed stark biointegration differences between resin and PA. Of the resin NICHE, only 1 of 4 had tissue ingrowth spanning the entirety of the cell reservoir, indicating full integration within the subQ space; 1 of 4 was mainly filled by clotted blood; and 2 of 4 were completely empty (Fig. 1f). In contrast, 4 of 4 PA devices were fully integrated within the subQ space (Fig. 1g). Material roughness and hydrophilicity influence cell adhesion and migration, which are key for NICHE subQ integration. Thus, we used atomic force microscopy (AFM) and contact angle analysis to characterize the roughness and hydrophilicity of resin and PA. Resin NICHE had average roughness and contact angle of 751.8 ± 181.2 nm and 76.19° , respectively; whereas for PA these were 1532 ± 657.5 nm and 91.99° (Fig. 1h-i). This indicated PA had a rougher, and more hydrophobic surface than resin, which could explain the difference in device integration. Histological assessment of cell reservoir tissue revealed similar vascular densities between resin (301.3 ± 9.0 vessels / mm²) and PA (293.7 ± 49.7 vessels / mm²) NICHE (Fig. 1j-k). However, only 2 resin NICHE had sufficient tissue to be processed for histology. Taken together, this data demonstrated that, although both resin and PA were biocompatible and well tolerated, PA was superior for NICHE biointegration and vascularization. As such, all further testing was performed with PA NICHE (hereinafter referred to as NICHE).

In vitro immunosuppressant release and toxicity

The rate of immunosuppressant delivery with NICHE can be adjusted by modifying the exchange surface area and drug concentration loaded¹⁷. Clinical islet transplantation requires multi-targeted immunosuppression, often employing antibody-based drugs. As such, we characterized the in vitro release of immunosuppressant Cytotoxic T lymphocyte-associated antigen-4-Immunoglobulin (CTLA4Ig), a fusion protein containing the extracellular domain of CTLA4 and human IgG1 (molecular weight: 92 kDa) from NICHE. Additionally, we used IgG (molecular weight: 150 kDa) as a surrogate molecule for full sized antibodies, to characterize drug release from NICHE. Congruent with polymer-based release,

CTLA4Ig had an initial burst release of ~18% of drug per day in the first 2 days, which steadily decreased and normalized to ~1-2% of drug per day by day 12 through day 30 (Fig. 1l). IgG displayed a different release profile with steady release between 5-8% per day for 10 days followed by a steady decrease thereafter, reaching ~0.5% by day 30 (Fig. 1l). These release profiles could be leveraged to recapitulate the clinical standard of sequential induction and maintenance phases of immunosuppression locally.

Local release of immunosuppressants into the transplant microenvironment entails constant islet exposure to drugs, which could be toxic. As such, we investigated the effect of CTLA4Ig and antilymphocyte serum (ALS), two clinically relevant immunosuppressants, on rat islet function via glucose stimulated insulin release (GSIR) in vitro (Fig. 1m-o). CTLA4Ig binds to CD80/CD86 receptors on antigen presenting cells (APCs), blocking co-stimulation signaling and, thus, T-cell activation²⁰. ALS is the rat analogue of thymoglobulin (ATG), a polyclonal pan-lymphocyte depleting antibody highly effective for islet transplantation²¹. Exposure to CTLA4Ig for 5 days did not affect islet function at any dose tested up to 1 mg/mL (Fig. 1m, o). Exposure to ALS showed a negative, albeit not statistically significant, effect on islet function at 1 mg/mL, which was set as the toxicity threshold (Fig. 1n). Moreover, exposure to a combination of 1 mg/mL CTLA4Ig and up to 0.4 mg/mL ALS did not exacerbate toxicity, indicating immunosuppressant co-delivery was safe for islets (Fig. 1o).

NICHE efficacy testing for allogeneic islet transplantation and diabetes reversal

We assessed NICHE efficacy for transplantation of allogeneic islets to treat diabetes in an immunocompetent rat model using Lewis rats as donors and Fischer 344 rats as recipients (Fig. 2a). NICHE loaded with syngeneic MSCs were subQ implanted in rats and allowed to vascularize for 6 weeks. At 2 weeks post-implantation, rats were rendered diabetic via streptozotocin injection. After pre-vascularization, diabetic rats were randomized into three immunosuppressive regimens (day 0): *NICHE* in which CTLA4Ig and ALS were loaded into the NICHE drug reservoir for local delivery; *IP*, which received a clinically relevant regimen consisting of induction with ALS+CTLA4Ig, followed by maintenance with CTLA4Ig alone; and *No IS*, which did not receive any immunosuppression. Three days later, leveraging the immunomodulatory and graft-promoting properties of MSCs^{22,23}, allogeneic islets were co-transplanted with syngeneic MSCs into the NICHE cell reservoir of all rats (Supplementary Fig. 2).

The isolated islets had typical morphology and responded to glucose stimulation in vitro prior to transplantation (Fig. 2b-c). By day 28 after islet transplantation, non-fasting blood glucose (BG) levels had dropped in NICHE and IP rats to 375.07 ± 117.68 mg/dL and 399.84 ± 124.36 mg/dL, respectively, whereas No IS control rats had significantly higher BG levels of 520.43 ± 24.39 mg/dL. To potentiate therapeutic effect, a second islet transplantation was performed on day 31 in rats from all groups. Within 10 days, 66.7% NICHE (8/12 animals) and 62.5% of IP (5/8 animals) became euglycemic (BG <200 mg/dL). Non-euglycemic rats (4 of 12 NICHE, 3 of 8 IP, and 4 of 4 No IS) were euthanized on day 63 as humane endpoint. Two rats in the NICHE group rejected their grafts prematurely on day 84 due to immunosuppressant release failure and were removed from study. On day 115, NICHE was explanted

from remaining IP rats and 2 of 5 NICHE rats, while the remaining 3 NICHE rats were followed up long term and explanted on day 193. Upon NICHE explantation, all rats immediately reverted to hyperglycemia, confirming diabetes correction was due to the transplanted islets that were retained within the NICHE. Moreover, to assess long-term glycemic control, HbA1c was quantified at the study endpoint. NICHE and IP rats had HbA1c comparable to healthy animals, below that of the desired threshold for diabetic patients of 7%²⁴ (Fig. 2e). In contrast, No IS rats had HbA1c >20%, indicative of extreme and unmanaged diabetes. It is noteworthy that the NICHE and IP rats that did not become euglycemic (~33%) maintained a significant improvement in BG levels compared to no IS controls until endpoint (Supplementary Fig. 3), suggesting the engrafted marginal islet mass had not been rejected.

Islet function of euglycemic NICHE and IP rats was assessed via intraperitoneal glucose tolerance test (ipGTT) on day 115 and compared to healthy and diabetic controls. NICHE and IP rats responded to glucose challenge similarly to healthy animals and significantly better than diabetic controls (Fig. 2f-g). Likewise, NICHE and IP rats had fasting c-peptide levels comparable to healthy rats that were significantly higher than diabetic controls, further confirming functional grafts (Fig. 2h). Weight fold change was used as an indicator of overall animal well-being. Upon diabetes induction, weight gain stalled in all animals (Fig. 2i). However, after islet transplantation, NICHE and IP rats had an immediate improvement in weight gain, while No IS rats remained with ill-thrift through endpoint, underscoring that the therapeutic benefit was exclusive to NICHE and IP groups.

Islets are densely vascularized in their native microenvironment; for transplantation, effective revascularization is imperative for successful engraftment and therapeutic function. As such, we quantified the percent islet area covered by blood vessels (Fig. 2j-m). Islets in the NICHE and IP groups averaged $12.02 \pm 2.06\%$ and $10.66 \pm 2.41\%$ vessel area, which was significantly higher than that of islets in the native pancreas ($7.58 \pm 1.63\%$), indicating the NICHE microenvironment was conducive to islet engraftment and efficient re-vascularization.

Taken together, we conclude that: 1) the pre-vascularized NICHE microenvironment was conducive to islet engraftment, 2) immunosuppression was needed to observe therapeutic benefit, and 3) local and systemic immunosuppression were equally as effective in preventing graft rejection and preserving islet function.

Local immunomodulation of the transplant microenvironment

The immunomodulation of the transplant microenvironment by local and systemic immunosuppression was characterized via imaging mass cytometry (IMC) analysis of cell reservoir tissue sections from euglycemic NICHE and IP rats as well as from rats with actively rejecting grafts; defined as transplanted, euglycemic rats that had spontaneous reversal to diabetic state and histological evidence of active rejection (Supplementary Fig. 4). Non-supervised cluster analysis of IMC samples classified cell populations into 13 clusters, the most predominant of which were: beta cells (insulin⁺), alpha cells

(glucagon⁺), blood vessels (α SMA⁺), cytotoxic T-cells (CD8⁺), and macrophages (CD68⁺). Alpha and beta cells were predominantly found in NICHE and IP sections and their distribution was consistent with islet morphology (Fig. 3a-b). In contrast, rejecting grafts showed minimal presence of alpha and beta cells, which were scattered and lacked typical islet morphology, suggestive of graft destruction (Fig. 3c-d). Moreover, blood vessels were present across all groups, with clear islet revascularization in NICHE and IP grafts. Rejecting grafts were densely infiltrated with cytotoxic T-cells and macrophages, whereas NICHE and IP grafts had significantly reduced number of these cell types (Fig. 3a-d). Infiltration of helper T-cells was limited across groups; however, higher levels were observed in rejecting grafts (Fig. 3d). The remaining cell population clusters consisted of various inflammatory cell types that were predominantly present in rejecting grafts (Fig. 3e-h). Of note, histological reconstructions and tSNE plots showed homologous cell distribution in NICHE and IP groups, underscoring local and systemic immunosuppression were equally effective at preserving islet viability.

Memory T-cell immunomodulation with local and systemic immunosuppression

To evaluate the systemic immunomodulatory effect of local and systemic immunosuppression, effector memory T-cell populations were assessed at endpoint in peripheral blood and spleen of NICHE and IP rats with viable grafts, as well as of rats with actively rejecting or previously rejected grafts. Rats with previously rejected grafts were defined as rats from the No IS cohort that never achieved euglycemia and whose histological assessment showed cell reservoirs that had been cleared of islets with minimal inflammation (Supplementary Fig. 4).

In the blood, CD4 and CD8 effector memory cells (Tem) frequencies were similar across NICHE, IP, and previously rejected rats, while rats with active rejection had significantly higher Tem levels (Fig. 3i, j). Blood CD4 and CD8 central memory cells (Tcm) did not differ statistically across groups; albeit a slight trend of increased CD8 Tcm cells was observed in rats with active rejection (Fig. 3i, j). In the spleen, similarly to the blood, CD4 Tem frequencies were similar between NICHE and IP rats (Fig. 3k). However, rats with past rejection showed higher splenic CD4 Tem frequencies (Fig. 3k). Similarly, NICHE and IP groups had comparable CD8 Tem and Tcm frequencies, which tended to be lower than in rats with past rejection (Fig. 3l; $p = 0.0913$ NICHE vs. past rejection; $p = 0.1645$ IP vs. past rejection) and active rejection (Fig. 3l; $p = 0.0529$ NICHE vs. active rejection; $p = 0.0954$ IP vs. active rejection).

Overall, NICHE and IP rats had similar frequencies across all memory T cells in blood and spleen that were consistently lower than in rats with active rejection. Meanwhile, rats with past rejection had increased memory T cell frequencies in the spleen and limited presence in the blood, suggesting homing rather than active circulation of these cell types. Taken together, this data indicated that local immunosuppression with NICHE attenuated memory T cell responses similarly to standard systemic delivery, effectively prolonging graft viability.

Drug biodistribution and systemic immunosuppression

Exposure to immunosuppressants was assessed via quantification of ALS and CTLA4Ig in plasma, peripheral organs, and the transplant microenvironment. In NICHE rats, ALS (0.6 mg) and CTLA4Ig (9 mg) were loaded into the drug reservoir on days 0, 28, and 56 for sustained release over time (Fig. 2a). In contrast, to recapitulate a clinical scenario, IP rats received induction with combination of ALS (10 mg i.p. on day 0) and CTLA4Ig (20 mg/kg i.p. on days 0, 3, 9, 12, 15), followed by maintenance with CTLA4Ig alone (20 mg/kg i.p. weekly) (Fig. 2a). In preparation for re-transplantation on day 31, IP rats received an additional ALS dose on day 28. Moreover, after observation of graft destabilization (Supplementary Fig. 5), NICHE rats received a “rescue” drug reservoir refilling with ALS and CTLA4Ig on day 157.

On day 6, IP rats averaged plasma ALS and CTLA4Ig levels of 358.18 µg/mL and 150.02 µg/mL, respectively. ALS levels dropped to 84.87 µg/mL by day 28 and, following readministration, increased to 188.70 µg/mL by day 35. Thereafter, plasma ALS steadily decreased, reaching 5.18 µg/mL at endpoint on day 112. On the other hand, CTLA4Ig levels in IP rats increased during induction, peaking at 246.59 µg/mL on day 14. During the maintenance phase, CTLA4Ig levels normalized to ~104.62 µg/mL through the remainder of the study.

Throughout the study, NICHE rats had ~36- and ~20-fold lower plasma ALS and CTLA4Ig levels than IP rats. On day 6, NICHE rats had circulating ALS levels of 1.33 µg/mL, which increased to 6.30 µg/mL by day 9 and remained steady through day 70 (Fig. 4a). Thereafter, plasma ALS levels steadily decreased and dropped below the limit of quantitation of 0.1 µg/mL after day 143. In accordance with in vitro release profile, CTLA4Ig exhibited a burst release, with peak plasma concentrations of 21.11 µg/mL on day 6 that steadily dropped to 8.21 µg/mL by day 28 (~2.5-fold) (Fig. 4b). On day 35, 7 days after drug reservoir refilling, CTLA4Ig levels rose to concentrations comparable to day 6 (18.56 µg/mL), indicating successful device refilling. Similarly, circulating levels steadily decreased, reaching 6.25 µg/mL on day 56, which was comparable to levels on day 28. Replenishment on day 56 restored CTLA4Ig concentrations within 7 days which, congruent with previous refilling procedures, decreased ~2.3-fold by day 84 (28 days post-refill). Drug reservoirs were not refilled after day 56 to assess how long drug loading could be deferred before islet function was compromised. Because of this, plasma CTLA4Ig levels continued to steadily decrease, reaching 0.02 µg/mL on day 157. Finally, after rescue refilling on day 157, circulating CTLA4Ig levels surged as expected, peaking at ~1 µg/mL on day 164.

Similarly to plasma, IP rats had significantly higher CTLA4Ig accumulation in peripheral tissues than NICHE rats, with 21-fold, 16-fold, 7-fold, and 22-fold higher levels in the kidney, liver, spleen, and lymph nodes, respectively (Fig. 4c). ALS levels in peripheral tissues were below the limit of quantitation in both NICHE and IP rats at endpoint (Fig. 4c). This was expected as NICHE rats were releasing low dose ALS and IP rats had received their last dose 84 days prior to endpoint (Fig. 2a). At the transplant microenvironment, NICHE rats had significantly higher CTLA4Ig and ALS levels in the cell reservoir, fibrotic capsule, and adjacent skin than IP rats (Fig. 4d). Taken together, this data indicated that localized dosing with NICHE enriched drug at the transplant microenvironment and significantly reduced drug accumulation in plasma and peripheral organs, decreasing the potential for systemic toxicity.

In addition to drug biodistribution, we assessed the degree of immunosuppression resulting from local and systemic delivery. Systemic immunosuppression with ALS causes lymphocyte depletion^{25,26}, while systemic CTLA4Ig is associated to decreased Treg frequencies²⁷. Thus, we quantified circulating T-cells and Tregs in NICHE and IP rats. As expected, following systemic ALS administration on days 0 and 28, IP rats exhibited acute lymphocyte depletion, indicative of profound immunosuppression (Fig. 4e). In contrast, circulating T-cell levels remained unchanged in NICHE rats throughout the study (Fig. 4e). Moreover, Treg frequencies in NICHE rats were similar to healthy controls, whereas IP rats had significantly lower levels (Fig. 4f). It is noteworthy that Treg quantification was performed on day 84, once total T-cell levels had been restored in IP rats, underscoring the immunosuppressive effect of systemic dosing (Fig. 4e). Taken together, this data indicated that the limited circulating levels in plasma resulting from local drug delivery with NICHE did not induce systemic effects and that, in contrast to the IP cohort, NICHE rats were not overtly immunosuppressed.

NICHE biocompatibility, islet engraftment, and local immunomodulation in NHP

Aiming at translation, we characterized the biocompatibility, islet engraftment, and local immunomodulation of NICHE in nonhuman primates (NHP). Healthy cynomolgus macaques (n=6) were subQ implanted with NICHE loaded with autologous MSCs to promote vascularization (Fig. 5a). Implanted NICHE left a minimal imprint on the macaque skin and no clinical signs of irritation or swelling were observed, indicating the implants were well tolerated (Fig. 5b). Additionally, transcutaneous drug reservoir loading and islet transplantation procedures were minimally invasive (Fig. 5c, d). Finally, NICHE explantation with intact fibrotic capsule was straightforward and required incisions smaller than 2 cm (Fig. 5e).

NICHE from 2 NHP were each explanted after 4 and 6 weeks of implantation to characterize integration in the subQ tissue, reactivity to the implant, and vascularization. By 4 weeks post-implantation, NICHE was well integrated into the subQ space with tissue spanning the entirety of the cell reservoir (Fig. 5f, g). The fibrotic capsule that formed around the implant was $\sim 100\ \mu\text{m}$, collagenous, and vascularized (Fig. 5h). Moreover, the NICHE had a lower reactivity score than control medical grade Ti implants, underscoring implant tolerability and biocompatibility (Fig. 5i). Labeling of cell reservoir tissue sections with blood vessel marker CD31 confirmed NICHE tissue was extensively vascularized (Fig. 5j). At 4 weeks post implantation, NICHE had $\sim 137 \pm 56$ vessels/ mm^2 that increased to $\sim 207 \pm 55$ vessels/ mm^2 by week 6, which accounted for $\sim 8.6\%$ of tissue area occupied by blood vessels (Fig. 5k-l).

After 6 weeks of prevascularization, NICHE from 3 of 4 NHP were transcutaneously filled with an immunosuppression cocktail (IS) consisting of anti-thymocyte globulin (ATG), CTLA4Ig, and anti-CD154 (CD154) for local delivery (Fig. 5c); 1 of 4 NHP did not receive IS loading and served as a negative control. αCD154 blocks the CD40-CD154 co-stimulatory pathway, halting pro-inflammatory cytokine production, effector T-cell activation, and B-cell class switch, while promoting T-reg expansion²⁸. Three days later, allogeneic islets from MHC mismatched cynomolgus macaques were transcutaneously co-

transplanted with autologous MSCs into the cell reservoir of all NHP (Fig. 5d). NICHEs were harvested from all animals 14 days post-transplantation as allograft rejection typically occurs within this timeframe in the absence of immunosuppression, thus permitting direct comparison between No IS and IS groups. After 2 weeks, IS NICHE had viable, insulin producing islets (Fig. 5m), whereas No IS NICHE only had limited presence of scattered cells (Fig. 5n), suggesting islets had been destroyed. Mass cytometry (CyTOF) analysis of cell reservoir tissue showed IS NICHE had approximately 4-fold fewer infiltrating leukocytes than No IS NICHE (Fig. 5o). Moreover, of the infiltrating leukocytes, IS NICHE had proportionally ~7-fold less B-cells and ~4-fold more NK cells than No IS NICHE; while CD4, CD8, and Treg populations did not differ between groups (Fig. 5p, Supplementary Fig. 6b-c). These results correlated with circulating cell populations (Supplementary Fig. 6d-e). Interestingly, the difference in NK populations was also present in the periphery pre-transplantation, suggesting an individual variation rather than a graft-dependent response (Supplementary Fig. 6f). IS NICHE had, suggesting a possible compensatory polarization of the immune response. Circulating CTLA4Ig levels peaked at 1.6 µg/mL on day 3 and decreased thereafter (Fig. 5q). In contrast, ATG and CD154 had similar and steady plasma levels throughout the study, averaging 0.88 ± 0.18 µg/mL. Moreover, IS was enriched at the transplant microenvironment and tended to be higher, yet only statistically significant for CD154, in the cell reservoir than the fibrotic capsule (Fig. 5q). Taken together this data confirmed the NICHE is biocompatible, well tolerated, and effectively vascularized in nonhuman primates. Additionally, localized IS delivery with NICHE prolonged allogeneic islet survival and modulated the local immune response, while significantly limiting systemic drug exposure.

Discussion

In the work presented here, we performed efficacy testing of the NICHE, an implantable cell encapsulation platform integrating direct vascularization and localized immunosuppressant delivery for transplantation of allogeneic islets to treat T1D. The NICHE was designed to meet critical criteria for long-term islet engraftment and therapeutic effect, namely: i) implant biocompatibility, ii) islet accessibility to oxygen, nutrients, and metabolic products to maintain function, iii) immune system evasion to prevent rejection, and iv) reduced footprint and invasiveness to improve translatability and patient acceptability.

Biocompatibility and biointegration of NICHE are paramount for islet engraftment and function. We explored use of resin and PA for NICHE fabrication as these are commonly used in implantable medical devices²⁹. Although both materials were biocompatible and minimally reactive (Fig. 1), resin NICHE integration was inconsistent; with only 25% of devices achieving full integration, as opposed to 100% of PA NICHE. PA is more hydrophobic than resin, which may increase macrophage adhesion and FBR^{30,31}. Indeed, we observed a slight increase in macrophage content within the fibrotic capsule of PA compared to resin devices (Supplementary Fig. 1). Moreover, the FBR to materials implanted subQ has been harnessed to create pre-vascularized sites for islet transplantation^{4,32}. We posit that, in a similar fashion, NICHE biointegration harnessed the FBR to drive vascularization into the cell reservoir, which was further potentiated by the tissue remodeling properties of MSCs^{19,33}. Furthermore, resin devices developed thin,

yet dense and almost avascular fibrotic capsules, while PA fibrotic layers were about 2-fold thicker yet tended to be lax and vascularized. This was in line with previous reports showing material a roughness $< 1 \mu\text{m}$, such as that of resin, promoted fibroblast spreading and dense fibrotic layers, whereas a roughness of $1 - 4 \mu\text{m}$, observed with PA, had the opposite effect³⁴. Thus, the density and composition, rather than the thickness, of the fibrotic layer may be better indicators of potential implant integration in the subQ space. Notably, the resin NICHE that achieved tissue colonization had a similar vascular density to PA NICHE, suggesting a threshold for subQ integration, where if the FBR can be harnessed adequately, the NICHE will be integrated and vascularized. Future studies on the specific mechanisms affecting implant biointegration will shed light on optimal materials for islet macroencapsulation. Ultimately, we confirmed PA is a suitable material for NICHE fabrication, integration, and vascularization.

Islet accessibility to oxygen, nutrients, and exchange of metabolic products was achieved through direct vascularization of the NICHE cell reservoir. In their native state, pancreatic islets are intimately connected to vasculature through intra-islet capillaries and receive $\sim 20\%$ of the pancreas blood supply albeit only comprising $\sim 1\%$ of the organ mass¹². Thus, we aimed to create a microenvironment that would recapitulate this vascular support by leveraging the proangiogenic, wound healing, and tissue remodeling properties of MSCs during implantation and transplantation^{23,35}. Moreover, device implantation with MSCs leads to denser and more mature vascular networks than implantation with growth factor depots¹⁹. Indeed, the vascularized environment engineered within NICHE was conducive to long-term engraftment of functional islets, achieving diabetes reversal in rats for over 150 days. Furthermore, while hypovascularization of islet grafts in direct vascularization strategies is commonplace³⁶, NICHE had higher intra-islet vascular density than in naïve pancreases. Interestingly, however, transplanted rats had a slight delay in glucose kinetics during intraperitoneal glucose tolerance testing, displaying peak BG levels at 30 min rather than at 15 min as typically observed in healthy animals. This is commonly observed with extrahepatic islet transplantation and is likely attributable to loss of direct insulin drainage into the portal circulation; thus, delaying insulin transport from the islets to the liver³⁷. Notwithstanding, this delay did not seem to have a significant clinical impact on overall BG control or animal wellbeing.

Transplantation of allogeneic cells and tissues requires immune system evasion to prevent rejection. Clinical islet transplantation employs potent systemic immunosuppression to abrogate the immune response at the expense of life-threatening adverse effects including toxicity, opportunistic infection, and neoplasm development^{2,3}. Here, we proved that localized immunosuppressant delivery with NICHE was as effective as the clinical standard of systemic delivery for allogeneic islet rejection prophylaxis in rats. Notably, NICHE delivery enriched immunosuppressants at the transplant microenvironment and limited systemic exposure by up to 36-fold, significantly reducing potential toxicity. Moreover, NICHE delivery did not induce measurable systemic immunosuppression, as evidenced by preserved populations of circulating lymphocytes and Tregs. This would have significant clinical impact in patient quality of life; not only by reducing the risk of opportunistic infection, but also by enabling boosting of the immune system against preventable diseases via vaccination, which lacks efficacy in immunocompromised patients^{38,39}. Various local immunomodulation strategies for islet transplantation have been explored

recently, including protein immobilization on biomaterial surface, chemical modification of the material, use of drug-releasing biomaterials, and co-transplantation with immunomodulatory cell types^{40,41}. However, although promising, biomaterial and cell-based strategies have the remaining challenges of being limited duration, difficult to replenish, and often rely on supplementation with systemic immunosuppression to effectively abrogate the allogeneic response⁴². To overcome these challenges, the NICHE was specifically designed for long-acting release, minimally invasive, transcutaneous refilling (every 6 months) via integrated silicone ports. This does not only allow for drug replenishment, but also for straightforward tailoring of the immunosuppressive cocktail throughout the graft lifespan as needed.

Local immunosuppression requires a shift in paradigm from standard systemic immunosuppression. Local immunosuppressant delivery as presented in this study remains largely unexplored. Thus, we decided to use a strategy that is systemically effective to allow for direct comparison between local and systemic administration. Since its introduction in the early 2000's, the Edmonton protocol, consisting of induction with a lymphocyte-depleting antibody followed by maintenance with sirolimus and tacrolimus, has been consistently used for clinical islet transplantation^{43,44}. However, sirolimus and tacrolimus-related islet toxicity make them unsuitable for use in a localized setting⁴⁵⁻⁴⁷. Combination of lymphocyte-depleting induction and costimulatory blockade maintenance prolongs allograft survival⁴⁸⁻⁵¹. Therefore, in this study, we used ALS and CTLA4Ig for efficacy testing in rats. Here, both local and systemic immunosuppression effectively prevented allogeneic islet rejection and downregulated the memory immune response in rats. However, significantly lower systemic drug levels as well as preservation of circulating immune cell populations with NICHE delivery suggested mechanistic differences between local and systemic administration. We posit that localized delivery with NICHE enriched immunosuppressants at the transplant microenvironment, where CTLA4Ig acted on surveilling APCs, while ALS neutralized infiltrating lymphocytes. Concomitantly, as Tregs were preserved, these likely played a synergistic immunomodulatory role for allograft protection⁵². Cross talk between MSCs and Tregs has been shown to enhance the immunosuppressive action of these cells, further contributing to localized immunosuppression⁵³. In contrast, lymphocyte depletion with systemic ALS essentially eliminated the rejecting cell pool in IP rats; while subsequent maintenance with high dose CTLA4Ig likely overwhelmed co-stimulation signaling and halted T-cell activation, preventing allograft rejection even in the context of reduced Tregs⁵⁴. Of note, the plasma CTLA4Ig concentrations of IP rats were comparable to those reported in human patients after systemic dosing⁵⁵. Therefore, as local delivery significantly limited systemic exposure, it is unlikely allograft survival in NICHE rats was merely due to immunosuppressant permeation into systemic circulation.

In macaques, expecting a more stringent immunological barrier than in rats, CD154 was added to the immunosuppressive cocktail. We theorized that tandem blockade of both main co-stimulation pathways would counteract the stringent, fully MHC-mismatched immunological barrier⁵⁶. In macaques, local IS partially abrogated the immune response, as viable, insulin-producing islets were only observed in animals receiving IS and grafts had 4-fold fewer infiltrating leukocytes than No IS controls. However, the proportion of regulatory, memory, and effector T cells were similar between IS and No IS animals both at

the graft site and in the periphery (Supplementary Fig. 6), suggesting stalling rather than modulation of the immune response. The efficacy of combination therapy with systemic ATG and CD154/CD40 pathway blockade has been documented^{50,57,58}, albeit the mechanism of action suggests heavy reliance on blockade at secondary lymphoid organs⁵⁹. Based on our data (Figs. 3 and 5), local immunosuppression should focus on stringent lymphocyte depletion to hold off infiltrating T and B lymphocytes, as well as polarization of the cell reservoir towards an immunosuppressive microenvironment (i.e., increasing Treg and M2 cells)^{60,61}. This should be achieved with agents that act on infiltrating cells in situ, rather than through immunomodulation at secondary lymphoid organs. Importantly, drug enrichment at the transplant microenvironment via NICHE opens an avenue for localized use of potent immunosuppressive agents whose high dose systemic use is limited by adverse effects. Ultimately, the results from this study unveiled an exciting path for exploration of local immunomodulation strategies for islet allograft survival.

A limitation to our study is that not all rats became euglycemic, attributable to insufficient islet engraftment. In this study, islets were transplanted within a collagen matrix that provided temporary extracellular support to promote viability (Supplementary Fig. 7)⁶². Moving forward, the transplant matrix could be enhanced with growth factors or other extracellular matrix components such as fibrin to maximize islet engraftment^{63,64}. It is noteworthy, however, that although not all rats became euglycemic, a significant benefit in non-fasting BG was observed for all animals transplanted in the NICHE and IP groups. This benefit in BG may translate into reduced exogenous insulin requirements and glucose lability, which improve patient quality of life⁶⁵. On another note, two NICHE animals rejected their grafts unexpectedly, which we attributed to device failure. Examination at endpoint showed these animals tended to have lower drug levels in cell reservoir tissue than others with viable grafts, suggesting insufficient drug release and concomitant inadequate immunosuppression (Supplementary Fig. 8). This could have resulted from faulty membrane porosity allowing rapid drug leakage and depletion. Moving forward, stringent quality control during device manufacturing in a clinical translation setting will help overcome these setbacks.

The NICHE was designed to reduce invasiveness and patient burden. Indeed, we demonstrated that all NICHE-related procedures could be conducted in an ambulatory setting in rats and nonhuman primates. The NICHE left a minimal imprint on skin after implantation, and fabrication in PA elicited a lower response than other materials used regularly in the clinic. NICHE deployment followed a carefully planned stepwise process to permit prevascularization, immunomodulation, and ultimately, islet engraftment. Our deployment approach aligns with current clinical islet transplantation protocol, where islet revascularization and multitargeted immunosuppression are required to achieve successful engraftment for T1D management. Moreover, SubQ implantation allows ease of access for repeated and straightforward refilling via minimally invasive injections. In this study, we refilled the NICHE drug reservoirs every 28 days, a frequency comparable to other long-acting drug formulations clinically available for applications such as migraine prevention or HIV treatment^{66–68}. Nevertheless, reducing procedure periodicity by prolonging immunosuppressant release would reduce patient burden. This could

be achieved by reducing the exchange surface area (e.g., membrane porosity) while increasing the amount of drug loaded¹⁷. Specifically, membranes with tightly controlled nanopore sizes as small as 2 nm have been used for sustained drug delivery^{69–72}; while recent development of transcutaneous refilling of solid therapeutics has the potential to improve loading efficiency by 1000-fold¹⁸. The versatility in NICHE design allows straightforward incorporation of these modifications. Finally, NICHE was resected en bloc, with intact fibrotic capsule and islets retained within the cell reservoir, underscoring feasible and safe retrieval.

In sum, the NICHE is the first platform to integrate direct vascularization and local immunosuppression into a single, implantable, replenishable device for allogeneic islet transplantation and long-term type 1 diabetes management. The results from this study demonstrated NICHE efficacy and pave a path for further development of the approach. Overall, the NICHE is a promising solution with the potential to transform the field of islet transplantation for safe and prolonged treatment of type 1 diabetes.

Materials And Methods

NICHE fabrication

NICHE main structure was designed using a solid modeling software (SolidWorks, Dassault Systèmes). The structure comprises a U-shaped drug reservoir (DR) that surrounds a central cell reservoir (CR). NICHE was fabricated by selective laser sintering (SLS) 3D printing (Sculpteo) using biocompatible polyamide (PA 2200, Electro Optical Systems) and by stereolithography (SL) 3D printing (Form 3b, Formlabs) using biocompatible resin (BioMed Clear, Formlabs). Two polyethersulfone (PES) nanoporous membranes (Sterlitech) were affixed between DR and CR, allowing for passive elution of immunosuppressants in the CR. The top and bottom surfaces of the CR were constructed by layering a set of 2 nylon meshes (Elko Filtering) per side on the main structure. The outer mesh had 100 μm x 100 μm openings while the inner had 300 μm x 300 μm openings. Ports for loading and refilling of CR and DR were made from implantable grade silicone adhesive (MED3-4213, Nusil) which was also employed in the assembling of membranes and meshes. NICHE components were autoclaved prior to assembly under a laminar flow hood using sterile technique. Fully manufactured NICHEs were sterilized with ethylene oxide gas at the Houston Methodist Research Institute Current Good Manufacturing Practice core. PA NICHEs were employed in the efficacy study (25 mm x 14.6 mm x 5 mm, CR: ~500 μL), biocompatibility and vascularity assessment in rats and in vivo testing in NHP (30.4 mm x 15.4 mm x 3.8 mm, CR: ~380 μL). Resin NICHEs (30 mm x 14.6 mm x 3 mm, CR: ~300 μL) were employed in biocompatibility and vascularity assessment in rats. NICHEs implanted in rats and NHPs had 100 nm and 30 nm nanoporous membranes, respectively.

Immunosuppressants

The immunosuppressants used for rat studies were CTLA4Ig (Abatacept, Bristol-Myers Squibb) and rabbit anti-lymphocyte serum (ALS; Accurate chemical); and for NHP studies anti-thymocyte globulin

(ATG; Sanofi), CTLA4Ig (Belatacept, Bristol-Myers Squibb), and anti-CD154 [5C8H1] (NIH Nonhuman Primate Reagent Resource, RRID: AB_2716324).

Scanning electron microscopy (SEM) imaging

Nylon meshes and membranes were sputtered with 7 nm iridium and imaged using Nova NanoSEM 230. Imaging was performed under high vacuum setting using a 5 kV electron beam at the Houston Methodist Research Institute Scanning Electron Microscopy and Atomic Force Microscopy Core.

Roughness assessment

PA and Resin NICHE roughness was measured via atomic force microscopy (AFM). AFM contact mode in air scans were performed using the Biocatalyst Atomic Force Microscope (Bruker) and the MultiMode 8 Atomic Force Microscope (Bruker) for PA and Resin, respectively, at the Houston Methodist Research Institute Scanning Electron Microscopy and Atomic Force Microscopy Core. The average surface roughness was calculated on 9 100 μm x 100 μm fields of view per material via NanoScope Analysis (Bruker).

Contact angle assessment

The water contact angle of PA and Resin NICHE samples ($n = 3/\text{material}$) was measured using the Attension Theta system (Biolin Scientific) for imaging and the One Attension software (Biolin Scientific) for analysis.

In vitro drug release

CTLA4Ig was labeled with Alexa-Fluor 647 NHS ester (Invitrogen) according to manufacturer's instructions. Conjugated CTLA4Ig (abatacept) was mixed with unlabeled CTLA4Ig at a 1:9 ratio and diluted to 55 mg/mL using USP water for injection (RM Bio). IgG-FITC conjugate (Sigma Aldrich) was diluted to 2 mg/mL using USP water for injection. Syringes with 25G needles were used to inject CTLA4Ig and IgG solutions in NICHE drug reservoirs integrated with 100 nm PES nanoporous membranes ($n = 4/\text{molecule}$). Loaded NICHEs were individually submerged in glass scintillation vials containing 22 mL of phosphate buffered saline (PBS) and incubated at 37°C under constant agitation. The sink solution was collected and fully replenished every third day. Samples of the sink solution were analyzed in duplicates using a plate reader to measure fluorescence (Synergy H4, Biotek).

Animal models

Eight-week-old male Lewis and Fischer 344 (F344) rats were used as donors and recipients, respectively (Charles River). All animals were maintained and used in conformity with guidelines established by the American Association for Laboratory Animal Science. Rats were kept in the Comparative Medicine Program facility at Houston Methodist Research Institute. All procedures were approved by the Houston Methodist Institutional Animal Care and Use Committee (IACUC) in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act.

For NHP studies, a male Mauritian cynomolgus monkey (*Macaca fascicularis*) purchased from the Mannheimer Foundation, Inc. (Homestead, FL) through the University of Miami Division of Veterinary Resources (DVR) was used as donor. The donor NHP was kept at the University of Miami animal facility. Female Vietnamese cynomolgus macaques (World Wide Primates Inc.), were used for biocompatibility studies ($n = 2$) and as recipients for islet transplant studies ($n = 4$). Recipient NHPs were kept at the AAALAC-I accredited Michale E. Keeling Center for Comparative Medicine and Research, The University of Texas MD Anderson Cancer Center (UTMDACC). Donor-recipient pairs were ABO compatible and mismatched as possible for MHC I and II alleles, identified via microsatellite analysis or deep sequencing⁷³. All experiments were carried out according to the provisions of the Animal Welfare Act, PHS Animal Welfare Policy, and the principles of the NIH Guide for the Care and Use of Laboratory Animals. All procedures were approved by the IACUC at UTMDACC and University of Miami.

Biocompatibility assessment

In rats, medical grade titanium (Ti) and resin discs (1 mm thick x 8 mm diameter) and resin and PA NICHE were implanted subQ for 6 weeks. In NHPs, PA NICHE were implanted subQ for 4-6 weeks. Ti (20 mm x 13 mm x 4.5 mm) devices implanted subQ for 16 weeks were used as reference⁷⁴. Retrieved implants were fixed and fibrotic capsules processed for histology. The thickness of the fibrotic capsule was measured on Masson's Trichrome-stained tissue sections with ImageJ software. At least 10 randomly selected areas were measured for each implant. Technical replicates were averaged, and biological replicates were pooled for comparison between groups. For implant reactivity scoring, H&E-stained tissue sections were scored by a blinded, board-certified pathologist using an established scoring system (Supplementary table 1)^{74,75}.

Generation, implantation and retrieval of NICHE with MSCs

For rat studies, MSCs isolated from bone marrow of F344 rats were obtained from Cyagen at P2 and expanded in vitro using StemXVivo Mesenchymal Stem Cell Expansion Media (R&D Systems). For NHP studies, autologous MSCs were isolated from whole blood using published methods^{19,76}. Briefly, whole blood was collected from each animal in sodium heparin tubes (BD). The mononuclear cell fraction was isolated using Ficoll and cultured in DMEM (Sigma) supplemented with 0.1 mM nonessential amino acids, 100-U/ml penicillin and streptomycin, 1 ng/ml basic fibroblast growth factor (FGF), 10% fetal calf serum (FCS), and 0.2 mM L-glutamine (Gibco). Adherent cells positive for markers CD105, CD90, CD29 and negative for markers CD14, CD34, CD45 were defined as MSCs. On implantation day, MSCs were suspended in a pluronic F-127 (Sigma) hydrogel (20% PF-127 in DMEM) and injected into the cell reservoir of NICHEs (5×10^5 per NICHE).

For implantation in rats, F344 rats were anesthetized using 1-2% isoflurane and appropriate anesthesia depth was confirmed by absence of pedal withdrawal reflex. Next, a 2 cm incision was made to create a subQ pocket, and NICHEs implanted in the dorsum. The wound was closed using clips, and rats recovered under heat supplementation until motor skills were regained. For implantation in NHPs, animals were pre-anesthetized with ketamine and anesthesia was maintained with 1-2% isoflurane. NICHE was inserted

into a subQ pocket in the dorsum through a 2 cm incision. The subQ tissue and skin were closed with an absorbable monofilament suture and animals recovered.

For retrieval, a 2 cm incision was made in anesthetized animals and NICHE resected en bloc with fibrotic capsule via blunt dissection. The subQ tissue and skin were closed with an absorbable monofilament suture and animals recovered.

Vascularity assessment

Resin and PA MSC-NICHE were implanted subQ in F344 rats for 6 weeks ($n=5$ per material). Tissue sections of explanted NICHE were stained with *B. simplicifolia* lectin to label blood vessels. For NHPs, 2 PA MSC-NICHE were implanted subQ in cynomolgus macaques ($n = 2$ NICHE/NHP). After 4 and 6 weeks, 1 NICHE was removed from each NHP, processed for histology, and tissue sections stained with CD31. Stained sections were visualized using EVOS imaging system coupled with a 40X objective (Life Technologies). Five and ten fields were randomly imaged per slide in rats and NHPs, respectively, and blood vessels were quantified by a blinded scientist. Blood vessel density was calculated as number of blood vessels per mm^2 . For rats, technical replicates were averaged, and biological replicates pooled for comparison between groups. For NHPs, all technical replicates per timepoint were pooled.

Five fields of view per NHP, per timepoint were randomly selected and vessel area was calculated using Eq. 1.:

$$\text{Vessel area (\%)} = \frac{\text{Area occupied by vessels}}{\text{Total section area}} \times 100$$

1

Rat islet isolation

Lewis rats were overdosed with isoflurane immediately prior to pancreas harvesting. Pancreas were perfused through the pancreatic duct with 9 mL Clzyme RI collagenase (Vitacyte) and 0.2 $\mu\text{g/mL}$ DNase (dornase alfa; Genentech) in Hanks balanced salt solution (HBSS; Gibco) with 10 mM HEPES (Gibco). Digestion was performed via static incubation in a water bath at 37°C for 19 min and 40 s. Next, enzymatic activity was quenched by adding 20 mL of 20% fetal bovine serum (FBS; Gibco) in HBSS and mechanical dissociation performed via vigorous shaking for 8 s. Tissue digest was washed 3 times with ice cold HBSS and strained through a 500 μm wire mesh. The tissue pellet was re-suspended in 15 mL 1.096 g/cm^3 OptiPrep (Sigma) and layered with 10 mL 1.068 g/cm^3 and 1.037 g/cm^3 OptiPrep and centrifuged at 1600 rpm for 20 min with no break. Islets were collected at the 1.096 g/cm^3 and 1.068 g/cm^3 interphase, washed with HBSS 3 times and cultured in RPMI-1640 media supplemented with 10% FBS, 1% penicillin/streptomycin, 20 mM HEPES, 5.5 mM glucose and 1 mM sodium pyruvate (all from Gibco) in a cell culture incubator set at 25°C and 5% CO_2 .

NHP islet isolation

For donor pancreatectomy, a midline abdominal incision from the xyphoid process to the pubis was made. The animal was exsanguinated, utilizing a 14 G catheter in the aorta, and the pancreas was dissected from the spleen, portal vein, and duodenum, with ligation of the pancreatic ducts. The pancreas was placed in Euro Collins Solution (Corning) and taken to the lab. Islet cell isolation was performed using modifications of the automated method for human islet isolation⁷⁷. The tissue was digested with Mammalian Tissue Free Liberase (Liberase MTF C/T, Roche), and discontinuous Euroficoll gradients (densities: 1.132; 1.108; 1.096; 1.037) were used for purification of islets from the pancreatic digest. The tissue was bottom-loaded with stock Ficoll and centrifuged in a COBE 2991 blood cell processor (Terumo).

In vitro glucose stimulated insulin release (GSIR).

Krebs buffered solution (KBS) was prepared with 115 mM NaCl, 24 mM NaHCO₃, 5 mM KCl, 1 mM MgCl₂, 0.1% bovine serum albumin (BSA), and 2.5 mM CaCl₂ (all from Fisher Scientific) and 25 mM HEPES (Gibco). Low (LG) and high (HG) glucose KBS was supplemented with 2.8 mM or 16.7 mM glucose (Gibco), respectively. Islets were transferred to 3 µm cell culture inserts in a 24-well plate and equilibrated with LG-KBS 1 h at 37°C. Next, inserts were transferred to 15 mL falcon tubes and centrifuged at 100 rcf for 15 s. Inserts with islets were transferred to a clean 24-well plate and incubated with LG-KBS for 1 h at 37°C followed by incubation with HG-KBS for 1 h at 37°C. The KBS was collected after each incubation step and analyzed for insulin content via ELISA (Alpco). The stimulation index was calculated as the HG-to-LG insulin secretion ratio.

In vitro drug toxicity assay

After incubation with CTLA4Ig, ALS or culture media (Vehicle) for 5 days, islet function was assessed via GSIR as described here.

Efficacy study in rats

F344 were implanted with MSC-NICHE subQ. After 2 weeks of implantation, rats were rendered diabetic via intraperitoneal (i.p.) streptozotocin (STZ; Sigma) injection of 65 mg/kg divided in 2 doses of 40 mg/kg and 25 mg/kg 5 days apart. BG was measured daily until diabetes was confirmed with 3 consecutive BG readings >300 mg/dL. After 6 weeks of vascularization, rats were randomized into 3 immunosuppressive groups (day 0): NICHE, IP, and No IS. NICHE rats ($n = 12$) received NICHE drug reservoir loading with 9 mg CTLA4Ig (30 mg/mL) and 0.6 mg ALS (2 mg/mL) for local delivery. IP rats ($n = 8$) received an induction regimen consisting of ALS (10 mg, i.p. day 0) and CTLA4Ig (20 mg/kg, i.p., days 0, 3, 6, 9, 12, 15) followed by maintenance with weekly CTLA4Ig (20 mg/kg, i.p.). No IS rats ($n = 4$) served as controls and did not receive immunosuppression. A cohort of healthy rats ($n = 5$) was used as reference. On day 3, all rats were co-transplanted with 3,000 islet equivalents (IEQ) and 4.5×10^6 syngeneic MSCs into the NICHE cell reservoir (Supplementary Fig. 2). On day 31, all rats received a second islet-MSCs transplant to boost therapeutic effect. NICHE rats drug reservoirs were refilled on days 28, 56, and 157. IP rats received a second ALS injection on day 28 in preparation for re-transplantation.

Body weight and BG were measured weekly, and euglycemia was determined as BG < 200 mg/dL. Islet function was assessed via intraperitoneal glucose tolerance test (IPGTT) on days 112 and 151, and fasting C-peptide quantification on day 112 via ELISA (Crystal Chem). Overall glycemic control was assessed via HbA1c quantification (Crystal Chem) at euthanasia for non-euglycemic rats and upon NICHE removal for euglycemic rats. NICHE ($n = 4$), IP ($n = 3$), and No IS ($n = 4$) rats that did not achieve euglycemia were euthanized on day 63 and NICHE, fibrotic capsule, skin, and peripheral tissues (spleen, liver, kidney, lymph node, and blood) collected for analysis. Rats that reverted to diabetic state (BG > 200 mg/dL) were euthanized and same tissues collected. On day 115, NICHEs were explanted from 2 of 5 euglycemic NICHE rats and 5 of 5 euglycemic IP rats in a survival surgery. On day 193, NICHEs were explanted from the remaining 3 NICHE rats. Upon removal, NICHEs were processed for histology and drug quantification. Rats were euthanized 2 days after NICHE removal and peripheral tissues collected for analysis. Circulating lymphocytes were measured on days 0, 3, 7, 14, 21, 28, 31, 56, 84, and 115, and Tregs on day 84 via flow cytometry.

NICHE assessment in NHPs

Cynomolgus macaques ($n = 4$) were implanted subQ with MSC-NICHE. After 6 weeks of vascularization, NICHEs of 3 NHPs were loaded with an immunosuppressant cocktail (ISC) consisting of 9 mg (30 mg/kg) CTLA4Ig, 3 mg (10 mg/kg) ATG, and 3 mg (10 mg/kg) anti-CD154 (day 0). One NHP did not receive ISC loading and served as a control. On day 3, 2000 allogeneic IEQ and 1×10^7 autologous MSCs were co-transplanted in NICHE of all NHPs. Blood was collected on days 0, 3, 10, and 17 for ISC quantification and on days 0, 3, and 17 for peripheral blood immunophenotyping. On day 17, NICHEs from all NHPs were explanted in a survival surgery and processed for histology, ISC quantification, and mass cytometry (CyTOF) analysis.

Islet transplantation

Islet doses were aliquoted into 15 mL falcon tubes and allowed to sediment (Supplementary Fig. 2). An MSC-collagen hydrogel was prepared by re-suspending MSC in 4 mg/mL neutralized, thermo-responsive collagen hydrogel (Advanced Biomatrix). Rat and NHP MSCs were procured as described in subsection *Generation and implantation of NICHE with MSCs*. Islet supernatant was carefully aspirated out without disturbing the islet pellet. Islets were re-suspended with MSC-collagen hydrogel using a wide tip and immediately loaded into a 1 mL syringe equipped with a 22G needle. The islet-MSC-hydrogel was immediately transcutaneously injected into NICHE cell reservoir through the silicone port. To prevent leakage, the needle was held in place for 3 min to allow for hydrogel polymerization.

NICHE drug reservoir loading

Immunosuppressant solution was loaded in a 1 mL syringe coupled with a 25 G needle. The syringe was advanced through the skin and a lateral silicone port into the drug reservoir. A second 25G needle was advanced in the same fashion through the contralateral silicone port to vent and prevent pressure buildup. Once both needles were in place, immunosuppressant solution was slowly pushed into the drug reservoir.

Immunosuppressant quantification

In rats, whole blood was collected in lithium heparin microtainers (BD) and plasma isolated via centrifugation. In NHPs, whole blood was collected in SST vacutainers (BD) and serum isolated via centrifugation. Tissues were homogenized using T-PER buffer (Thermo Scientific) supplemented with Protease Inhibitor Tablets (Thermo Scientific). CTLA4Ig was quantified using CTLA-4 Soluble Human ELISA Kit (Invitrogen); ALS was quantified with Easy-titer Rabbit IgG (Thermo Scientific); ATG was quantified with Rabbit Fc kit (Perkin Elmer); and anti-CD154 was quantified with Human IgG Kappa MAb kit (Perkin Elmer)

BG monitoring and IPGTT

BG levels were assessed via tail prick with a commercial veterinary glucometer (AlphaTrack, Zoetis). For IPGTT, rats were fasted for 16 h and injected i.p. with 3 g/kg of 50% dextrose solution (Northeast Medical Products). BG readings were obtained at baseline and at 15, 30, 60, 90, and 120 minutes post-injection.

Histology and immunohistochemistry analysis

Upon harvesting, tissues were fixed in 10% formalin for 5 days. Fixed tissues were dehydrated in standard ethanol and xylene washes followed by paraffin embedding. Tissues were cut in 5 µm sections and stained with hematoxylin-eosin (H&E) and Masson's Trichrome using standard technique at the Research Pathology Core of Houston Methodist Research Institute. For blood vessel staining, sections were stained with *Bandeiraea simplicifolia* lectin (Sigma), CD31 (ab28364, Abcam), or insulin [C27C9] (Cell Signaling) as previously described^{17,19}. Sections were visualized using EVOS imaging system (Life Technologies).

Islet revascularization assessment

Pancreas or cell reservoir tissue sections were stained with *B. simplicifolia* lectin and visualized using EVOS imaging system coupled with a 40X objective (Life Technologies). The islet area within a field of view was isolated and the percent islet area covered by blood vessels quantified. Biological replicates were pooled for comparison between groups.

Imaging mass cytometry (IMC) analysis

IMC analysis was performed at the ImmunoMonitoring Core at the Houston Methodist Research Institute. Antibodies were conjugated with metals following the Fluidigm protocol as previously described⁷⁸ (Supplementary table 2). For staining, NICHE sections were baked at 60°C overnight followed by deparaffinization in xylene and rehydration in alcohol gradients (absolute ethanol, absolute ethanol:deionized water 90:10, 80:20, 70:30, 50:50, 0:100) for 10 min each. Epitope retrieval was done in a water bath at 95°C in Tris-Tween 20 buffer pH 9 for 20 min. Sections were blocked with 3% BSA in tris-buffered saline, followed by staining overnight at 4°C with markers in Supplementary table 1 and nuclear staining with Cell-ID Intercalator (Fluidigm). Slides were air-dried and ablated with Hyperion (Fluidigm) for data acquisition. Data were segmented by ilastik and CellProfiler. Histology topography cytometry

analysis toolbox (HistoCAT) and R scripts were used to quantify cell number and generate tSNE plots⁷⁹. Analysis was performed on 2 ROI/sample and $n = 3$ /group for a total of $n = 6$ ROI/group.

CyTOF analysis

To prepare single cell suspensions, NICHE cell reservoir tissue was cut into 2 mm x 2 mm pieces and digested using collagenase/hyaluronidase in DMEM (Stem Cell) at 37°C for 35 min with orbital shaking at 100 rpm. Digestion was quenched with 2% FBS in PBS and digest filtered through a 40 µm strainer. Cells were pelleted and RBC lysed with ACK lysing buffer (Quality Biological). Cells were washed twice and re-suspended with 2% FBS in PBS. Single cell suspension was stained with metal-tag viability dye for 5 min and washed with cell staining buffer (Fluidigm), followed by sequential staining of surface and intracellular markers. Next, cells were stained with Cell ID Intercalator Ir (Fluidigm) at 4°C overnight. The next day, cells were washed and prepared for acquisition with Helios (Fluidigm). The data was analyzed by Cytofbank. Briefly, data was normalized, gated out beads and dead cells, and gated on singlet and CD45⁺ cell population, which was selected to perform a tSNE analysis. The tSNE plots were gated according to the gating strategy described in Supplementary table 3. The ratio of cell populations within CD45⁺ cells was quantified by Cytobank and plotted with Prism (Graphpad).

Flow cytometry analysis

Rat model. For memory T cell analysis at endpoint, spleens were disaggregated into single cell suspensions via mechanical dissociation in PBS with 5 mM EDTA and filtered through a 40 µm cell strainer. Red blood cells were removed via incubation with ACK lysis buffer (Quality Biological). Cells were washed and, following incubation with FC blocker (CD32, BD Biosciences), 1×10^6 cells were stained with CD45, CD3, CD4, CD8a, CD44, CD62L, and viability dye. Cells were washed with 2% FBS in PBS with 5 mM EDTA and fixed with IC fixation buffer (Invitrogen). For blood analysis, 100 µL of whole blood anticoagulated with EDTA was stained with same markers as the spleen followed by incubation with 1-step Fix/Lyse Solution (eBioscience). Cells were transferred to 5 mL FACS tubes with 40 µm cell strainer (Corning) and washed twice with 2% FBS in PBS. For circulating lymphocyte analysis, 100 µL whole blood was stained as above with CD45 and CD3. For circulating Treg analysis, 100 µL of whole blood was stained as above with CD45, CD3, CD4, CD25, and viability dye, followed by fixation with eBioscience fixation/permeabilization buffer (Invitrogen), permeabilization with 1X permeabilization buffer (Invitrogen), and intracellular staining with Foxp3. Cells were washed twice and re-suspended in 2% FBS in PBS with 5 mM EDTA. Data was acquired on LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo v10 software (FlowJo, LCC). Analysis was performed after exclusion of debris, doublets and nonviable cells. Effector memory T cell (Tem) population was defined as CD3⁺CD4⁺CD44⁺CD62L⁻ or CD3⁺CD8⁺CD44⁺CD62L⁻. Central memory T cell population (Tcm) was defined as CD3⁺CD4⁺CD44⁺CD62L⁺ or CD3⁺CD8⁺CD44⁺CD62L⁺. Circulating lymphocytes were defined as CD45⁺CD3⁺. Treg population was defined as CD3⁺CD4⁺CD25⁺Foxp3⁺. Antibodies used are detailed in Supplementary table 4.

NHP model. Immunophenotyping of whole blood were undertaken via immunofluorescent staining and flow cytometric analysis as previously described with antibodies specified in Supplementary table 5⁴¹. All flow cytometry samples included a Live/Dead Fixable Near-IR Dead Cell Stain (Molecular Probes) for viability assessment and were run on a Becton Dickinson LSR II cytometer and analyzed using Kaluza software (version 1.5a, Beckman Coulter).

Assessment of islet viability in collagen matrix

One-hundred Lewis rat islets were embedded in 100 µL of 4 mg/mL collagen matrix (RatCol, Advanced Biomatrix) and gelled in a 96-well plate at 37°C. Once gelled, 100 µL supplemented culture media was added and incubated at 37°C. Control islets were incubated in 200 µL supplemented culture media. After 7 days, samples were stained using LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) and images captured using a BX61 Olympus microscope and analyzed with ImageJ software. Islet viability was calculated using Eq. 2

$$\text{Isletviability (\%)} = \frac{\text{Liveisletarea}}{\text{Liveisletarea} + \text{Deadisletarea}} * 100$$

2 Statistical analysis

Results are expressed as mean ± standard deviation. Statistical analyses were performed using Prism software (GraphPad Software Inc.). Normality testing was performed and Student’s t-test, one-way analysis of variance (ANOVA) and post-hoc analyses were used to determine statistical significance of differences among groups. Specific analysis method, number of replicates and *p* values are specified in each figure legend.

Declarations

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgements.

The authors are grateful to Dr. Marco Farina for insightful discussion and information. The authors thank Dr. Jianhua (James) Gu from the electron microscopy core of Houston Methodist Research Institute; Dr. Andreana L. Rivera, Yuelan Ren, and Sandra Steptoe from the research pathology core of Houston Methodist Research Institute; Drs. Yitian Xu, Licheng Zhang, and Shu-Hsia Chen from the ImmunoMonitoring Core of Houston Methodist Research Institute; Dr. David L. Haviland and Nicole Vaughn from the flow cytometry core of Houston Methodist Research Institute; Melissa A. Willman, Alex Rabassa and Waldo L. Diaz from the Diabetes Research Institute for support in blood

immunophenotyping and islet isolation in NHP studies; and Luke Segura, Elizabeth Lindemann, Dana Salazar, Bharti Nehete, and Dr. Greg Wilkerson from the Michale E. Keeling Center for Comparative Medicine and Research at UTMDACC for support in NHP studies. The authors also thank graphic designer Virginia Faccioto (virginia.faccioto@gmail.com) for the preparation of schematics and illustrations. Funding support from Juvenile Diabetes Research Foundation 1-INO-2018-595-A-N (AG), Vivian L. Smith Foundation (AG), and Houston Methodist Research Institute (AG).

Conflict of Interest Declaration.

A.G., S.C., and J.P-M. are inventors of intellectual properties licensed by NanoGland, LLC.

References

1. Rickels, M. R. & Robertson, R. P. Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions. *Endocr Rev* **40**, 631–668, doi:10.1210/er.2018-00154 (2019).
2. Buxeda, A., Redondo-Pachon, D., Perez-Saez, M. J., Crespo, M. & Pascual, J. Sex differences in cancer risk and outcomes after kidney transplantation. *Transplant Rev (Orlando)* **35**, 100625, doi:10.1016/j.tre.2021.100625 (2021).
3. Wang, D., Meiser, B., Eisen, H. J. & Eifert, S. in *Heart Failure* (eds David S. Feldman & Paul Mohacsi) 241-253 (Springer International Publishing, 2019).
4. Paez-Mayorga, J. *et al.* Emerging strategies for beta cell transplantation to treat diabetes. *Trends in Pharmacological Sciences*, doi:https://doi.org/10.1016/j.tips.2021.11.007 (2021).
5. Gamble, A., Pepper, A. R., Bruni, A. & Shapiro, A. M. J. The journey of islet cell transplantation and future development. *Islets* **10**, 80–94, doi:10.1080/19382014.2018.1428511 (2018).
6. Farina, M., Alexander, J. F., Thekkedath, U., Ferrari, M. & Grattoni, A. Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond. *Adv Drug Deliv Rev*, doi:10.1016/j.addr.2018.04.018 (2018).
7. Hu, S. & de Vos, P. Polymeric Approaches to Reduce Tissue Responses Against Devices Applied for Islet-Cell Encapsulation. *Front Bioeng Biotechnol* **7**, 134, doi:10.3389/fbioe.2019.00134 (2019).
8. Carlsson, P. O. *et al.* Transplantation of macroencapsulated human islets within the bioartificial pancreas betaAir to patients with type 1 diabetes mellitus. *Am J Transplant* **18**, 1735–1744, doi:10.1111/ajt.14642 (2018).
9. Wang, L. H. *et al.* An inverse-breathing encapsulation system for cell delivery. *Sci Adv* **7**, doi:10.1126/sciadv.abd5835 (2021).
10. Wang, L. H. *et al.* A bioinspired scaffold for rapid oxygenation of cell encapsulation systems. *Nat Commun* **12**, 5846, doi:10.1038/s41467-021-26126-w (2021).
11. Lee, J.-H., Parthiban, P., Jin, G.-Z., Knowles, J. C. & Kim, H.-W. Materials roles for promoting angiogenesis in tissue regeneration. *Progress in Materials Science* **117**, 100732, doi:https://doi.org/10.1016/j.pmatsci.2020.100732 (2021).

12. Muratore, M., Santos, C. & Rorsman, P. The vascular architecture of the pancreatic islets: A homage to August Krogh. *Comp Biochem Physiol A Mol Integr Physiol* **252**, 110846, doi:10.1016/j.cbpa.2020.110846 (2021).
13. Farina, M. *et al.* 3D Printed Vascularized Device for Subcutaneous Transplantation of Human Islets. *Biotechnol J* **12**, doi:10.1002/biot.201700169 (2017).
14. Farina, M. *et al.* Transcutaneously refillable, 3D-printed biopolymeric encapsulation system for the transplantation of endocrine cells. *Biomaterials* **177**, 125–138, doi:10.1016/j.biomaterials.2018.05.047 (2018).
15. Farina, M. *et al.* Implantable 3D Printed Encapsulation System for Cell Transplantation, Organogenesis and Drug Release, Patent No. PCT/US2018/056203, Apr 25, 2019.
16. Grattoni, A., Paez-Mayorga, J. & Capuani, S. Transcutaneously refillable cell confinement platform with local trophic factor delivery. U.S. Provisional Pat. Ser. No. 63/043,439. June 24, 2020. United States patent (2020).
17. Paez-Mayorga, J. *et al.* Neovascularized implantable cell homing encapsulation platform with tunable local immunosuppressant delivery for allogeneic cell transplantation. *Biomaterials* **257**, 120232, doi:10.1016/j.biomaterials.2020.120232 (2020).
18. Di Trani, N., Pons-Faudoa, F., Sizovs, A., Shelton, K., Marzinke, M., Nehete, P., Grattoni, A. Extending drug release from implants via transcutaneous refilling with solid therapeutics. *Advanced Therapeutics*, doi:10.1002/adtp.202100214 (2021).
19. Paez-Mayorga, J. *et al.* Enhanced In Vivo Vascularization of 3D-Printed Cell Encapsulation Device Using Platelet-Rich Plasma and Mesenchymal Stem Cells. *Adv Healthc Mater* **9**, e2000670, doi:10.1002/adhm.202000670 (2020).
20. Bluestone, J. A., St Clair, E. W. & Turka, L. A. CTLA4Ig: bridging the basic immunology with clinical application. *Immunity* **24**, 233–238, doi:10.1016/j.immuni.2006.03.001 (2006).
21. Bellin, M. D. *et al.* Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. *Am J Transplant* **12**, 1576–1583, doi:10.1111/j.1600-6143.2011.03977.x (2012).
22. Li, X. *et al.* Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis. *J Diabetes Res* 2020, 5860417, doi:10.1155/2020/5860417 (2020).
23. Wang, M., Yuan, Q. & Xie, L. Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application. *Stem Cells Int* 2018, 3057624, doi:10.1155/2018/3057624 (2018).
24. Redondo, M. J. *et al.* The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence. *Diabetes Care* **44**, 301–312, doi:10.2337/dc20-1978 (2021).
25. Mohty, M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. *Leukemia* **21**, 1387–1394, doi:10.1038/sj.leu.2404683 (2007).
26. (Genzyme Corporation, Cambridge, MA, 2020).

27. Riella, L. V. *et al.* Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. *Am J Transplant* **12**, 846–855, doi:10.1111/j.1600-6143.2011.03929.x (2012).
28. Pinelli, D. F. & Ford, M. L. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. *Immunotherapy* **7**, 399–410, doi:10.2217/imt.15.1 (2015).
29. Maitz, M. F. Applications of synthetic polymers in clinical medicine. *Biosurface and Biotribology* **1**, 161–176, doi:10.1016/j.bsbt.2015.08.002 (2015).
30. Akilbekova, D., Philip, R., Graham, A. & Bratlie, K. M. Macrophage reprogramming: influence of latex beads with various functional groups on macrophage phenotype and phagocytic uptake in vitro. *J Biomed Mater Res A* **103**, 262–268, doi:10.1002/jbm.a.35169 (2015).
31. Xu, Z., Hwang, D.-G., Bartlett, M. D., Jiang, S. & Bratlie, K. M. Alter macrophage adhesion and modulate their response on hydrophobically modified hydrogels. *Biochemical Engineering Journal* **165**, 107821, doi:https://doi.org/10.1016/j.bej.2020.107821 (2021).
32. Pepper, A. R. *et al.* A prevascularized subcutaneous device-less site for islet and cellular transplantation. *Nat Biotechnol* **33**, 518–523, doi:10.1038/nbt.3211 (2015).
33. Guillamat-Prats, R. The Role of MSC in Wound Healing, Scarring and Regeneration. *Cells* **10**, doi:10.3390/cells10071729 (2021).
34. Doloff, J. C. *et al.* The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans. *Nat Biomed Eng* **5**, 1115–1130, doi:10.1038/s41551-021-00739-4 (2021).
35. Melchiorri, A. J., Nguyen, B. N. & Fisher, J. P. Mesenchymal stem cells: roles and relationships in vascularization. *Tissue Eng Part B Rev* **20**, 218–228, doi:10.1089/ten.TEB.2013.0541 (2014).
36. Pepper, A. R., Gala-Lopez, B., Ziff, O. & Shapiro, A. M. J. Revascularization of Transplanted Pancreatic Islets and Role of the Transplantation Site. *Clinical and Developmental Immunology* 2013, 352315, doi:10.1155/2013/352315 (2013).
37. Latres, E., Finan, D. A., Greenstein, J. L., Kowalski, A. & Kieffer, T. J. Navigating Two Roads to Glucose Normalization in Diabetes: Automated Insulin Delivery Devices and Cell Therapy. *Cell Metab* **29**, 545–563, doi:10.1016/j.cmet.2019.02.007 (2019).
38. Bertrand, D. *et al.* Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. *J Am Soc Nephrol* **32**, 2147–2152, doi:10.1681/ASN.2021040480 (2021).
39. Husain, S. A. *et al.* Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. *Kidney Int Rep* **6**, 1699–1700, doi:10.1016/j.ekir.2021.04.017 (2021).
40. Wang, X. *et al.* Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells. *Adv Sci (Weinh)* **8**, e2003708, doi:10.1002/advs.202003708 (2021).
41. Kenyon, N. S. *et al.* Extended survival versus accelerated rejection of nonhuman primate islet allografts: Effect of mesenchymal stem cell source and timing. *Am J Transplant*, doi:10.1111/ajt.16693 (2021).

42. Kuppan, P. *et al.* Co-localized immune protection using dexamethasone-eluting micelles in a murine islet allograft model. *Am J Transplant* **20**, 714–725, doi:10.1111/ajt.15662 (2020).
43. Shapiro, A. M. *et al.* Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N Engl J Med* **343**, 230–238, doi:10.1056/NEJM200007273430401 (2000).
44. Anazawa, T., Okajima, H., Masui, T. & Uemoto, S. Current state and future evolution of pancreatic islet transplantation. *Ann Gastroenterol Surg* **3**, 34–42, doi:10.1002/ags3.12214 (2019).
45. Berman, D. M., Ruiz, P., Jr., Blandino-Rosano, M., Bernal-Mizrachi, E. & Kenyon, N. S. Steroid-Free Immune Suppression Impairs Glycemic Control in a Healthy Cynomolgus Monkey. *Cell Transplant* **28**, 262–268, doi:10.1177/0963689718823505 (2019).
46. Shapiro, A. M., Pokrywczynska, M. & Ricordi, C. Clinical pancreatic islet transplantation. *Nature reviews. Endocrinology* **13**, 268–277, doi:10.1038/nrendo.2016.178 (2017).
47. Kezic, A., Popovic, L. & Lalic, K. mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand? *Oxid Med Cell Longev* 2018, 2640342, doi:10.1155/2018/2640342 (2018).
48. Bottino, R. *et al.* Safe use of anti-CD154 monoclonal antibody in pig islet xenotransplantation in monkeys. *Xenotransplantation* **24**, doi:10.1111/xen.12283 (2017).
49. Giannis, D., Moris, D. & Cendales, L. C. Costimulation Blockade in Vascularized Composite Allotransplantation. *Front Immunol* **11**, 544186, doi:10.3389/fimmu.2020.544186 (2020).
50. Berman, D. *et al.* in *American Transplant Congress 2021* Vol. 21 <https://atcmeetingabstracts.com/abstract/at-1501-a-novel-and-clinically-applicablecd1540l-specific-monoclonal-antibody-promotes-islet-allograft-survival-in-nonhuman-primates>. (American Journal of Transplantation, 2021).
51. Berman, D. M. *et al.* Bioengineering the Endocrine Pancreas: Intraomental Islet Transplantation Within a Biologic Resorbable Scaffold. *Diabetes* **65**, 1350–1361, doi:10.2337/db15-1525 (2016).
52. Deppong, C. M. *et al.* CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-beta. *J Immunol* **191**, 3082–3089, doi:10.4049/jimmunol.1300830 (2013).
53. Gazdic, M. *et al.* Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury. *Liver Transpl* **24**, 687–702, doi:10.1002/lt.25049 (2018).
54. Schwarz, C. *et al.* The Immunosuppressive Effect of CTLA4 Immunoglobulin Is Dependent on Regulatory T Cells at Low But Not High Doses. *Am J Transplant* **16**, 3404–3415, doi:10.1111/ajt.13872 (2016).
55. Ma, Y. *et al.* Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. *Acta Pharmacol Sin* **30**, 364–371, doi:10.1038/aps.2009.13 (2009).
56. Kim, S. C. *et al.* Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. *Am J Transplant* **17**, 1182–1192, doi:10.1111/ajt.14197 (2017).

57. Kenyon, N. S. *et al.* Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. *Proc Natl Acad Sci U S A* **96**, 8132–8137, doi:10.1073/pnas.96.14.8132 (1999).
58. Kenyon, N. S. *et al.* Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. *Diabetes* **48**, 1473–1481, doi:10.2337/diabetes.48.7.1473 (1999).
59. Benichou, G., Gonzalez, B., Marino, J., Ayasoufi, K. & Valujskikh, A. Role of Memory T Cells in Allograft Rejection and Tolerance. *Front Immunol* **8**, 170, doi:10.3389/fimmu.2017.00170 (2017).
60. Marino, J., Paster, J. & Benichou, G. Allorecognition by T Lymphocytes and Allograft Rejection. *Front Immunol* **7**, 582, doi:10.3389/fimmu.2016.00582 (2016).
61. Li, Y. *et al.* Immunosuppressive PLGA TGF-beta1 Microparticles Induce Polyclonal and Antigen-Specific Regulatory T Cells for Local Immunomodulation of Allogeneic Islet Transplants. *Front Immunol* **12**, 653088, doi:10.3389/fimmu.2021.653088 (2021).
62. Stephens, C. H. *et al.* In situ type I oligomeric collagen macroencapsulation promotes islet longevity and function in vitro and in vivo. *Am J Physiol Endocrinol Metab* **315**, E650-E661, doi:10.1152/ajpendo.00073.2018 (2018).
63. Schaschkow, A. *et al.* Glycaemic control in diabetic rats treated with islet transplantation using plasma combined with hydroxypropylmethyl cellulose hydrogel. *Acta Biomater* **102**, 259–272, doi:10.1016/j.actbio.2019.11.047 (2020).
64. Yu, M. *et al.* Islet transplantation in the subcutaneous space achieves long-term euglycaemia in preclinical models of type 1 diabetes. *Nat Metab* **2**, 1013–1020, doi:10.1038/s42255-020-0269-7 (2020).
65. Rickels, M. R. *et al.* Defining Outcomes for beta-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop. *Transplantation* **102**, 1479–1486, doi:10.1097/TP.0000000000002158 (2018).
66. Orkin, C. *et al.* Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. *N Engl J Med* **382**, 1124–1135, doi:10.1056/NEJMoa1909512 (2020).
67. Aschenbrenner, D. S. First Extended-Release Injectable Drug Therapy for HIV. *Am J Nurs* **121**, 24–25, doi:10.1097/01.NAJ.0000751096.82989.00 (2021).
68. Ferrari, M. D. *et al.* Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study. *J Neurol Neurosurg Psychiatry*, doi:10.1136/jnnp-2021-327480 (2021).
69. Jeon, G., Yang, S. Y. & Kim, J. K. Functional nanoporous membranes for drug delivery. *Journal of Materials Chemistry* **22**, 14814–14834, doi:10.1039/C2JM32430J (2012).
70. Chua, C. Y. X. *et al.* Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody. *Advanced Therapeutics* **3**, 2000055, doi:https://doi.org/10.1002/adtp.202000055 (2020).
71. Bruno, G. *et al.* Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale. *Nat Commun* **9**, 1682, doi:10.1038/s41467-018-04133-8 (2018).

72. Geninatti, T. *et al.* Sustained Administration of Hormones Exploiting Nanoconfined Diffusion through Nanochannel Membranes. *Materials (Basel)* **8**, 5276–5288, doi:10.3390/ma8085241 (2015).
73. Shortreed, C. G. *et al.* Characterization of 100 extended major histocompatibility complex haplotypes in Indonesian cynomolgus macaques. *Immunogenetics* **72**, 225–239, doi:10.1007/s00251-020-01159-5 (2020).
74. Pons-Faudoa, F. P. *et al.* Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates. *Adv Ther (Weinh)* **4**, doi:10.1002/adtp.202000163 (2021).
75. Su, J. T. *et al.* A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques. *Antimicrob Agents Chemother* **64**, doi:10.1128/AAC.01893-19 (2020).
76. Nichols, J. E. *et al.* Neurogenic and neuro-protective potential of a novel subpopulation of peripheral blood-derived CD133+ ABCG2+CXCR4+ mesenchymal stem cells: development of autologous cell-based therapeutics for traumatic brain injury. *Stem Cell Res Ther* **4**, 3, doi:10.1186/scrt151 (2013).
77. Berman, D. M. Isolation of Pancreatic Islets from Nonhuman Primates. *Adv Exp Med Biol* **938**, 57–66, doi:10.1007/978-3-319-39824-2_5 (2016).
78. Liu, H. C. *et al.* Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. *Int J Radiat Oncol Biol Phys*, doi:10.1016/j.ijrobp.2020.07.2326 (2020).
79. Schapiro, D. *et al.* histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. *Nat Methods* **14**, 873–876, doi:10.1038/nmeth.4391 (2017).

Figures

Figure 1

NICHE design and characterization. **a** Optical image of NICHE and Annotated rendering of NICHE and scanning electron microscopy (SEM) images of the two-layer mesh and nanoporous membrane. Longitudinal section of NICHE is representative for clarity. Representative Masson's trichrome staining of fibrotic capsule around **b** resin and **c** PA devices implanted in rats for 6 weeks. **d** Quantification of fibrotic capsule thickness around medical grade titanium (Ti; $n = 5$), resin ($n = 5$), and PA ($n = 4$) devices

implanted subQ for 6 weeks in rats, mean $\pm$ SD, one way analysis of variance (ANOVA) *** $p < 0.001$. **e** Implant reactivity scores of Ti ($n = 5$), resin ($n = 5$), and PA ($n = 4$) devices implanted subQ for 6 weeks in rats, mean $\pm$ SD, one-way ANOVA, n.s. $p = 0.1117$. Optical images showing cross sections of **f** resin and **g** PA NICHE implanted subQ for 6 weeks. Dashed lines indicate cell reservoir. **h** Resin and PA roughness quantified using atomic force microscopy ($n = 9$), mean $\pm$ SD, unpaired two-tailed student's t-test ** $p < 0.01$. **i** Contact angle analysis of resin and PA devices ($n = 3$), mean $\pm$ SD, unpaired two-tailed student's t-test *** $p < 0.001$. **j** Resin and PA NICHE cell reservoir tissue sections stained with blood vessel marker *B. simplicifolia* lectin; vessels in red pointed by black arrow heads. **k** Vascular density quantification of resin ($n = 2$) and PA ($n = 4$) cell reservoir tissue, mean $\pm$ SD, unpaired two-tailed student's t-test n.s. $p = 0.852$. **l** Daily percent in vitro release of CTLA4Ig and IgG ($n = 4$) NICHE drug reservoir, mean $\pm$ SD. Static glucose stimulated insulin release (GSIR) of rat islets after 5 days of incubation with **m** CTLA4Ig, **n** ALS, and **o** CTLA4Ig + ALS ($n = 3$ per condition), mean $\pm$ SD, one-way ANOVA, n.s. $p > 0.05$ of each condition versus vehicle (0 mg/mL).

Figure 2

NICHE efficacy testing for allogeneic islet transplantation in immunocompetent diabetic model. **a** Study design. STZ = streptozotocin. Yellow circles indicate islet transplant. Black triangles indicate NICHE explant. Blue triangles indicate NICHE drug reservoir refilling. Gray triangles indicate systemic CTLA4Ig administration. Red triangles indicate systemic ALS administration. **b** Micrograph depicting Lewis rat isolated islets prior to transplantation. **c** Static glucose stimulated insulin release of Lewis rat isolated

islets prior to transplantation ($n = 4$), mean $\pm$ SD, unpaired two-tailed student's t-test *** $p < 0.001$. **d** Blood glucose measurements of diabetic F344 rats transplanted with islets in NICHE cell reservoir receiving local (NICHE; $n = 8$ to day 91, $n = 5$ to day 116, $n = 3$ to day 195) or systemic (IP; $n = 5$ to day 116) immunosuppression with CTLA4Ig and ALS, no immunosuppression (No IS; $n = 4$ to day 63), and healthy controls ($n = 6$ to day 116, $n = 1$ to day 195), mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test of BG at endpoint prior to explant (n.s. $p = 0.9618$ NICHE versus IP, $p = 0.5768$ NICHE versus healthy, $p = 0.9792$ IP versus healthy; *** $p < 0.001$ No IS versus NICHE, IP, and healthy). iTx = islet transplant; DM = diabetes mellitus. Only NICHE and IP rats that achieved euglycemia are plotted. **e** HbA1c of NICHE ($n = 4$), IP ($n = 5$), healthy ($n = 5$), and No IS ($n = 3$) rats at endpoint. Dotted line indicates 7% threshold indicative of adequate glycemic control for diabetic patients. **f** BG curves and **g** area under the curve (AUC) of intraperitoneal glucose tolerance test (ipGTT) on day 112 of NICHE ($n = 4$), IP ($n = 4$), healthy ($n = 3$), and diabetic control ($n = 3$) rats, mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test (** $p < 0.01$ DM Ctrl versus NICHE and IP; *** $p < 0.001$ DM Ctrl versus healthy; n.s. $p = 0.6179$ NICHE versus IP, $p = 0.6531$ NICHE versus healthy, $p = 0.1565$ IP versus healthy). **h** Fasting C-peptide in plasma on day 112 of NICHE ($n = 4$), IP ($n = 4$), healthy ($n = 3$), and diabetic control ($n = 3$) rats, mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test (** $p < 0.01$ DM Ctrl versus NICHE and IP; * $p < 0.05$ DM Ctrl versus healthy; n.s. $p = 0.9998$ NICHE versus IP, $p = 0.9999$ NICHE versus healthy, $p > 0.9999$ IP versus healthy). **i** Weigh fold change to baseline of NICHE ($n = 8$), IP ($n = 5$), Healthy ($n = 5$), and No IS ($n = 4$), mean $\pm$ SD. Tissue sections stained with blood vessel marker *B. simplicifolia* lectin (vessels in red) of **j** pancreas from healthy rats, and cell reservoir tissue of euglycemic **k** NICHE and **l** IP rats. Black arrow heads indicate capillaries. **m** Quantification of percent islet area comprised of vessels in healthy rat pancreas ($n = 8$) and NICHE ($n = 4$) and IP rats ($n = 5$), mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test (** $p < 0.01$; * $p < 0.05$; n.s. $p = 0.5719$ NICHE versus IP).

Figure 3

Immunomodulation with NICHE and IP delivery. Imaging mass cytometry (IMC) of cell reservoir tissues from **a** NICHE, **b** IP, and **c** rats with rejected grafts. **d** IMC cell populations quantification ($n = 6$), mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test per population (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; n.s. $p > 0.05$). **e-h** tSNE plots of IMC data. Pooled data from $n = 6$ ROI per group. Cell populations were defined as follow: Cytotoxic T-Cell (Tc) CD45⁺CD3⁺CD8⁺, Helper T-Cell (Th) CD45⁺CD3⁺CD4⁺,

Macrophages (Mac) CD45⁺CD68⁺, Neutrophils CD45⁺MPO⁺. Flow cytometry analysis of **i** blood CD4⁺ memory T cells, **j** blood CD8⁺ memory T cells, **k** spleen CD4⁺ memory T cells, and **l** spleen CD8⁺ memory T cells at endpoint in NICHE ($n = 5$) and IP ($n = 7$) rats, and grafts with active ($n = 3$) or past ($n = 3$) rejection, mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test per population ($*p < 0.05$; $**p < 0.01$; n.s. $p > 0.05$).

Figure 4

Drug biodistribution and systemic immunosuppression. Plasma levels of **a** ALS and **b** CTLA4Ig of NICHE ($n = 12$ to day 63, $n = 8$ to day 92, $n = 5$ to day 112, $n = 3$ to day 192) and IP ($n = 8$ to day 63, $n = 5$ to day 112) rats, mean $\pm$ SD, unpaired two-tailed student's t-test between NICHE and IP overall average concentrations, ($***p < 0.001$). Black triangles indicate drug reservoir reloading. Red triangle indicates systemic ALS bolus. LOQ = limit of quantitation. Quantification of immunosuppressants in **c** peripheral organs and **d** transplant microenvironment at endpoint of NICHE and IP rats ($n = 8$), mean $\pm$ SD, unpaired two-tailed student's t-test between NICHE and IP rats for each organ ($*p < 0.05$; $**p < 0.01$; $***p < 0.001$; n.s. $p > 0.05$; n.q. = not quantifiable). FC = fibrotic capsule. **e** Quantification of lymphocytes in blood expressed as fold change to day 0 of NICHE ($n = 8$ to day 56, $n = 5$ to day 115), IP ($n = 5$), and rats receiving vehicle ($n = 4$). **f** Quantification of Tregs in blood on day 84 of NICHE, IP, and healthy rats ($n = 5$), mean $\pm$ SD, one-way ANOVA with Tukey's multiple comparisons test ($***p < 0.001$; n.s. $p = 0.1643$).

Figure 5

NICHE biocompatibility, islet engraftment, and local immunomodulation in NHP. **a-e** NICHE deployment strategy in nonhuman primates (NHPs). **f** Gross and **g** H&E-stained micrograph showing a cross-section of NICHE after 4 weeks of subcutaneous implantation in NHP. **h** Masson's Trichrome staining of fibrotic capsule formed around NICHE after 4 weeks of subQ implantation in NHP. **i** Implant reactivity scores of Ti ($n = 4$) and PA ($n = 4$) devices implanted subQ in NHP, mean $\pm$ SD, unpaired two-tailed student's t-test, (** $p < 0.01$). **j** Micrograph of NICHE cell reservoir tissue stained with blood vessel marker CD31. **k** Vascular density quantification of NICHE implanted subQ for 4 and 6 weeks ($n = 20$ ROI), mean $\pm$ SD, unpaired two-tailed student's t-test, *** $p < 0.001$. **l** Quantification of percent area of NICHE tissue occupied by blood vessels after 4 and 6 weeks of implantation ($n = 20$ ROI), mean $\pm$ SD, unpaired two-tailed student's t-test (n.s. $p = 0.1988$). **m-n** Micrograph of NICHE tissue stained for insulin 14 days post-transplant in IS and No IS NHPs. **o-p** Quantification of cell inside NICHE of IS ($n = 3$) and No IS ($n = 1$) NHPs 14 days post-

transplant. **q** Quantification of immunosuppressants in plasma and NICHE microenvironment of IS NHP ($n = 3$). Cell Res = cell reservoir; FC = fibrotic capsule.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryInformation.docx](#)